Navigation Links
Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
Date:4/23/2009

NEW HAVEN, Conn., April 23 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin(TM) (laromustine) Injection has received a standard review classification by the U.S. Food and Drug Administration (FDA). Therefore, a user fee goal date of December 12, 2009 for a decision by the FDA with respect to the approval of the Company's NDA has been established.

The Company had previously announced the acceptance of the NDA filing for review by the FDA on April 16, 2009. The NDA presents data for Onrigin(TM) as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The NDA is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these 140 patients had two or more risk factors that predicted for a poor prognosis.

Alan Kessman, Chief Executive Officer, commented, "Our level of excitement continues to grow as we move forward in the FDA's process of reviewing our NDA. We will continue to work closely with the FDA on the filing with the objective of achieving approval for Onrigin(TM) in its first indication in the United States." He added, "The positive news today is that we can expect to have an FDA decision this year."

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin(TM)(laromustine) Injection and Triapine(R). The FDA is reviewing a New Drug Applicat
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
3. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
4. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
5. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
6. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
7. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
8. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Governor of Yucatán, Rolando Zapata Bello, presented the ... event is organized by the Microcredit Summit Campaign in ... Microenterprise Financing Program ( PRONAFIM ) and will take ... Convention Center Yucatan Siglo XXI in the city of ... to host the 17th Microcredit Summit logistically but especially ...
(Date:8/28/2014)... August 28, 2014 Bank lending to the ... year, down by 0.13% in real terms, and continuing to ... new study by UHY, the international accountancy network. , UHY ... businesses in particular, the credit crunch lingers on. , UHY ... the last year have been wiped out by inflation. Over ...
(Date:8/28/2014)... fall from trees and learn to flap their forelimbs to ... pump their "arms" to get aloft? , The answer is ... University of California, Berkeley, study provides a new piece of ... midair, a talent that could have helped their ancestors learn ... study looked at how baby birds, in this case chukar ...
(Date:8/28/2014)... Albert Einstein College of Medicine of Yeshiva University ... Sudan ebolavirus (SUDV), one of the two most lethal strains ... now devastating West Africa. First identified in 1976, SUDV has ... that have killed more than 400 people in total. The ... , Between 30 and 90 percent of people infected with ...
(Date:8/28/2014)... herbal medication practitioner in Melbourne for back pain ... of intensive care and emergency physicians to call ... complementary medications. , Writing in Emergency Medicine ... for Emergency Medicine, emergency medicine trainees Dr Angelly ... Care Unit at the Royal Melbourne Hospital and ...
Breaking Medicine News(10 mins):Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:Drug shows promise against Sudan strain of Ebola in mice 2Health News:Deadly remedy: Warning issued about Chinese herbal medicine 2
... Annual JMP Securities Research Conference ... on May 21 - ... Meeting on May 22 -, SAN DIEGO, May 14 Ardea Biosciences, Inc.,(Nasdaq: ... Annual Research Conference. Additionally, Ardea will be,hosting a live webcast and conference call of ...
... 14 Biotel Inc. (OTC Bulletin,Board: BTEL) announced results ... earnings of $99,000, or $0.03 per diluted share, on ... or $0.07 per diluted,share, on revenues of $2,990,000 for ... ended March 31, 2008, Biotel had net earnings of ...
... Patients more likely to survive using chemoradiation, and new ... -- Tonsil and tongue cancers linked to human papillomavirus ... treatments, while those that express high levels of a ... most deadly, a new study concludes. , University of ...
... other treatments work well, too, giving patients options , , WEDNESDAY, ... kind supports the use of a popular three-drug regimen for ... drugs is a good alternative. , But an older ... Sharon Riddler, assistant professor of medicine at the University of ...
... , , WEDNESDAY, May 14 (HealthDay News) -- A bundle of ... cardiovascular disease in a study of older Swedish men, researchers ... long process that might one day lead to widespread medical ... such as high blood pressure and cholesterol, said Dr. Johan ...
... Honored for Their Research -, PALO ALTO, ... Ph.D. students and two professors with the company,s ... field of organic,chemistry. The winners participated in Roche,s ... on the important role of organic,chemistry in pharmaceutical ...
Cached Medicine News:Health News:Ardea Biosciences Announces Upcoming Corporate Meetings 2Health News:Ardea Biosciences Announces Upcoming Corporate Meetings 3Health News:Biotel Announces Profitable Third Quarter Ended March 31, 2008 2Health News:HPV Tied to Better Tongue, Tonsil Cancer Outcomes 2Health News:Study Supports Popular HIV Drug Regimen 2Health News:Study Supports Popular HIV Drug Regimen 3Health News:Biomarkers Predict Heart Deaths 2Health News:Biomarkers Predict Heart Deaths 3Health News:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 2Health News:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 3
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 ... has been commenced in the United States District Court ... on behalf of investors who purchased Galectin Therapeutics Inc. ... 6, 2014 and July 28, 2014. For ... The complaint alleges that during the Class Period the ...
(Date:8/28/2014)...   Edison Nation Medical , the premier ... for product ideas to improve the health and ... through the 6-month search ( www.EdisonNationMedical.com/Seniors ) will ... healthcare retailers with whom Edison Nation Medical has ... 65 and older. The objective of ...
(Date:8/28/2014)...  Seres Health, a clinical-stage therapeutics company developing ... microbiome, announced today that Dr. David Cook ... Chief Scientific Officer, will be presenting at the ... (ICAAC). The presentation will highlight the scientific and ... bacterial spores derived from the human microbiome, and ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2
... CRAIGAVON, Northern Ireland , August 2, 2010 ... a range of solutions,specifically designed to meet the needs of the ... , ... biopharma companies in adopting,biomarker strategies to enable them to better understand ...
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that ... Healthcare Conference on Thursday, August 5, 2010 at 1:15 ... held at the Sheraton New York Hotel & Towers.  Steve Worland, Ph.D., ... Anadys and its clinical development programs. , ...
Cached Medicine Technology:Almac Launch Biomarkers for Biopharma 2Almac Launch Biomarkers for Biopharma 3Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference 2
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
Nebulizer Adapter Kit 6"...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
Medicine Products: